Takase Yuuki, Itoh Yoshiyuki, Ohtakara Kazuhiro, Kawamura Mariko, Ito Junji, Oie Yumi, Ono Tamami, Sasaki Yutaro, Nishida Ayumi, Naganawa Shinji
Department of Radiology, Nagoya University Graduate School of Medicine,Nagoya, Japan.
Nagoya J Med Sci. 2021 May;83(2):251-258. doi: 10.18999/nagjms.83.2.251.
Glottic carcinoma is the most common laryngeal cancer. The outcomes for T1 bulky Glottic carcinoma and T2N0 Glottic carcinoma after radiation therapy alone are unsatisfactory. This study was conducted to evaluate the efficacy and safety of unique concurrent chemoradiotherapy regimen using S-1 for early glottic cancer. Concurrent chemoradiotherapy consisted of 60 Gy in 30 fractions with once-daily, orally administered S-1 exclusively within three to six hours prior to each irradiation. Twenty-one consecutive patients treated with this regimen were retrospectively reviewed. Initial complete remission was achieved in all patients without any subsequent local and/or regional recurrences to the last follow-up. The 4-year local control, overall survival, and disease-free survival rates were all 100%. No significant toxicities were observed, except for three cases with Grade 3 acute dermatitis.This regimen is highly effective and well-tolerated, and these results encourage further research to long-term efficacy and functional preservation.
声门癌是最常见的喉癌。单纯放疗后，T1期巨大声门癌和T2N0期声门癌的治疗效果并不理想。本研究旨在评估使用S-1的独特同步放化疗方案对早期声门癌的疗效和安全性。同步放化疗包括30次分割给予60 Gy，每天一次，仅在每次放疗前3至6小时口服S-1。对连续21例接受该方案治疗的患者进行回顾性分析。所有患者均实现了初始完全缓解，直至最后一次随访均无任何后续局部和/或区域复发。4年局部控制率、总生存率和无病生存率均为100%。除3例出现3级急性皮炎外，未观察到明显毒性。该方案疗效显著且耐受性良好，这些结果鼓励进一步研究其长期疗效和功能保留情况。
